SCHEMBL4006830

SCHEMBL4006830

COc1ccc(C(=O)N[C@H]2CCCN(c3ccccc3)C2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.59
PPARA Q07869 2/20 0.59
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 2/20 0.57
PKM P14618 1/20 0.57
BTK Q06187 4/20 0.56
JAK3 P52333 4/20 0.54
POLB P06746 1/20 0.53
MMP2 P08253 1/20 0.53
MMP13 P45452 1/20 0.53
LCK P06239 1/20 0.52
MAPT P10636 1/20 0.52
NR4A1 P22736 1/20 0.52
RAB9A P51151 1/20 0.52
MCL1 Q07820 1/20 0.52
CNR1 P21554 1/20 0.52
GRM5 P41594 1/20 0.51
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4006837 1.00 PPARD (0.59) PPARDPPARAKMT2AALDH1A1MEN1
SCHEMBL4005581 0.89 USP30 (0.61) PPARDPPARAPKMBTKMMP2
SCHEMBL4005574 0.89 USP30 (0.61) PPARDPPARAPKMBTKMMP2
SCHEMBL4003576 0.88 ALDH1A1 (0.59) PPARDPPARAALDH1A1PKMMAPT
SCHEMBL4003572 0.88 ALDH1A1 (0.59) PPARDPPARAALDH1A1PKMMAPT
SCHEMBL4006928 0.85 MEN1 (0.61) PPARDPPARAKMT2AMEN1RAB9A
SCHEMBL4006925 0.85 MEN1 (0.61) PPARDPPARAKMT2AMEN1RAB9A
SCHEMBL31759405 0.84 CNR1 (0.71) PPARDPPARACNR1
SCHEMBL31759487 0.84 CNR1 (0.71) PPARDPPARACNR1
SCHEMBL25260564 0.84 MAPT (0.57) PPARDPPARAKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 PPARD 234/4885PPARA 340/4885KMT2A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.